Skip to main content
. 2024 May 3;11:1289928. doi: 10.3389/fmed.2024.1289928

Table 2.

Baseline characteristics of the patients.

Characteristics Trial group (n = 55) Control group (n = 59) total (n = 114) Group comparison
t/χ2/z p
Age (year) 70.65 ± 8.07 67.78 ± 8.59 69.17 ± 8.43 t = 1.84 0.069
Gender χ2 = 0.18 0.675
Male n (%) 44 (80.00) 49 (83.05) 93 (81.58)
Female n (%) 11 (20.00) 10 (16.95) 21 (18.42)
BMI 23.01 ± 3.03 22.81 ± 3.38 22.91 ± 3.20 t = 0.33 0.743
Smoking status χ2 = 0.118 0.731
Not smoking n (%) 26 (47.27) 26 (44.07) 52 (45.61)
Currently smoking n (%) 29 (52.73) 33 (55.93) 62 (54.39)
Symptoms
Shortness of breath 4.47 ± 1.90 4.17 ± 1.67 4.32 ± 1.79 t = 0.90 0.368
Cough 2.44 ± 1.13 2.17 ± 0.85 2.30 ± 1.00 t = 1.41 0.161
Sputum 2.33 ± 1.20 2.34 ± 0.99 2.33 ± 1.09 t = 0.06 0.955
Acute attack
Frequency (times) 1.00 (0.00,7.00) 1.00 (0.00, 9.00) 1.00 (0.00, 9.00) Z = 0.318 0.751
Hospitalization
Frequency (times) 1.00 (0.00, 4.00) 0.00 (0.00, 9.00) 1.00 (0.00, 9.00) Z = 1.079 0.281
Duration (day) 10.00 (0.00, 65.00) 0.00 (0.00, 63.00) 9.00 (0.00, 65.00) Z = 0.969 0.333
Lung function
FVC 2.09 ± 0.64 2.40 ± 0.80 2.25 ± 0.74 t = 2.25 0.026
FVC% 64.46 ± 15.08 68.37 ± 17.66 66.48 ± 16.51 t = 1.27 0.208
FEV1 1.07 ± 0.34 1.31 ± 0.53 1.20 ± 0.46 t = 2.91 0.004
FEV1% 43.94 ± 13.51 47.52 ± 15.90 45.79 ± 14.84 t = 1.29 0.200
FEV1/FVC 52.34 ± 10.25 54.65 ± 10.63 53.54 ± 10.47 t = 1.18 0.240
CAT 16.36 ± 6.01 15.58 ± 5.83 15.96 ± 5.91 t = 0.71 0.480
6MWT 365.89 ± 115.81 373.14 ± 116.81 369.64 ± 115.87 t = 0.33 0.740
mMRC Z = 0.969 0.333
0 n (%) 3 (5.45) 4 (6.78) 7 (6.14)
1 n (%) 14 (25.45) 23 (38.98) 37 (32.46)
2 n (%) 30 (54.55) 18 (30.51) 48 (42.11)
3 n (%) 8 (14.55) 13 (22.03) 21 (18.42)
4 n (%) 0 (0.00) 1 (1.69) 1 (0.88)

BMI = weight (Kg)/height2(m). Hospitalizations within the 12-month period before screening were self-reported.